Hepatotoxicity in rifampin-isoniazid treated patients related to their rate of isoniazid inactivation.
D000469:Alkaline Phosphatase / Q000097:blood; D001663:Bilirubin / Q000097:blood; D001798:Blood Proteins / Q000032:analysis; D056486:Chemical and Drug Induced Liver Injury; D004342:Drug Hypersensitivity / Q000209:etiology; D004357:Drug Synergism; D005260:Female; D006801:Humans; D007538:Isoniazid / Q000008:administration & dosage / Q000009:adverse effects* / Q000378:metabolism / Q000627:therapeutic use; D008099:Liver / Q000187:drug effects; D008111:Liver Function Tests; D008297:Male; D012293:Rifampin / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D000637:Transaminases / Q000097:blood; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy
D001798:Blood Proteins; D000637:Transaminases; D000469:Alkaline Phosphatase; D001663:Bilirubin; D007538:Isoniazid; D012293:Rifampin